Sleep Disorders

Sleep Disorders is a comprehensive clinical reference app
for healthcare professionals covering the full spectrum of
central hypersomnias, parasomnias, and circadian rhythm
disorders. Based on ICSD-3, AASM, EAN, and NICE guidelines.

CONDITIONS COVERED:

NARCOLEPSY TYPE 1 (with cataplexy)
Complete ICSD-3 diagnostic criteria. Orexin/hypocretin
deficiency, HLA-DQB1 association, cataplexy versus mimics
table (epilepsy, TIA, FND), classic tetrad, CSF orexin
interpretation, and full diagnostic pathway.

NARCOLEPSY TYPE 2 (without cataplexy)
MSLT criteria, NT1 versus NT2 versus IH comparison table,
MSLT confounders, reclassification risk.

IDIOPATHIC HYPERSOMNIA
Sleep inertia (sleep drunkenness), unrefreshing naps,
prolonged nocturnal sleep, diagnostic criteria, treatment
including modafinil and lower-sodium oxybate (FDA 2023).

KLEINE-LEVIN SYNDROME
Recurrent hypersomnia episodes, hyperphagia, behavioural
changes, adolescent epidemiology, lithium prevention.

REM SLEEP BEHAVIOUR DISORDER
Dream enactment, loss of REM atonia, neurodegeneration
risk (80-90% conversion to Parkinson/MSA/DLB -- Postuma
2019), prodromal markers, clonazepam versus melatonin.

RESTLESS LEGS SYNDROME AND PLMD
URGE diagnostic criteria, secondary causes including iron
deficiency, augmentation warning, NICE NG218 2023
treatment ladder with pregabalin first-line.

CIRCADIAN RHYTHM DISORDERS
Delayed sleep phase, Non-24, advanced sleep phase, shift
work disorder, jet lag. Light therapy, melatonin
chronobiology, tasimelteon for N24.

OBSTRUCTIVE SLEEP APNOEA
STOP-BANG screening tool, AHI diagnostic thresholds,
PSG versus home sleep testing, CPAP indications, MAD,
residual EDS management, DVLA driving rules.

SLEEP INVESTIGATIONS
Full ESS scoring grid (8 situations), PSG channels and
sleep architecture, MSLT protocol and interpretation,
CSF orexin-A, actigraphy, HLA typing.

DRUG TREATMENTS -- 10 detailed drug cards:
Modafinil, armodafinil, pitolisant, methylphenidate,
dexamfetamine, venlafaxine, clomipramine, fluoxetine,
sodium oxybate (Xyrem), lower-sodium oxybate (Lumryz).
Full drug-by-indication summary table.

KEY FEATURES:
-- ICSD-3 diagnostic criteria for all conditions
-- STOP-BANG OSA screening tool
-- ESS scoring with interpretation guide
-- DVLA UK driving regulations for narcolepsy and OSA
-- Cataplexy versus epilepsy/TIA/FND differential table
-- Augmentation warning for dopamine agonists in RLS
-- RBD neurodegeneration risk and counselling guidance
-- Font size A- / A+ controls
-- 15 tappable references to guidelines and trials
-- Works fully offline

REFERENCES INCLUDE:
ICSD-3 (AASM 2014), AASM Clinical Practice Guidelines
2021, NICE NG218 RLS 2023, EAN Narcolepsy Guidelines
2022, IRLSSG Diagnostic Criteria 2014, NICE TA609
Pitolisant, NICE TA320 Sodium Oxybate, Postuma RBD
Neurodegeneration 2019, Johns ESS 1991, BNF.

For qualified healthcare professionals only.
NOT a regulated medical device under MHRA Software
Guidance 2020, EU MDR Article 2(1), and FDA 21st
Century Cures Act Section 3060.